Risk factors associated with fluconazole resistance in Candida parapsilosis candidemia: A case-case study.
Candida parapsilosis
candidemia
fluconazole
intensive care units
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
06
03
2024
received:
23
11
2023
accepted:
11
03
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
ppublish
Résumé
Candida species are among the most important invasive pathogens in intensive care units (ICUs). Non-albicans species including Candida parapsilosis (C. parapsilosis) has increased in recent years. Fluconazole is the leading antifungal agent but resistance is a concern among C. parapsilosis species. The aim of this study was to determine the factors associated with fluconazole resistance in patients with candidemia due to C. parapsilosis in ICUs. This case-case study was conducted in a 750-bed, tertiary hospital between 2015 and 2021. Patients with fluconazole-resistant C. parapsilosis candidemia constituted the 'cases of interest' group and patients with fluconazole-susceptible C. parapsilosis candidemia constituted the 'comparison cases' group. Demographic and clinical data of the patients were recorded. Logistic regression analysis was performed using the backward elimination method to determine the independent predictors of fluconazole-resistant C. parapsilosis bloodstream infections. The study included 177 patients. In the cultures of these patients, 76 (43%) fluconazole-resistant, 13 (7.3%) fluconazole-reduced susceptible, and 88 (49.7%) fluconazole-susceptible isolates were found. In the regression analysis the risk factors for fluconazole-resistant C. parapsilosis bloodstream infection, malignancy, immunosuppressive treatment, history of intra-abdominal surgery, hypoalbunemia, previous fluconazole use, and SOFA score were found to be associated in univariate analysis. In multivariate regression analysis, history of intra-abdominal surgery (OR: 2.16; 95% CI: 1.05-4.44), hypoalbuminemia (OR: 2.56; 95% CI: 1.06-6.17) and previous fluconazole use (OR: 3.35; 95% CI: 1.02-11) were found to be independent predictors. In this study, a significant correlation was found between candidemia due to fluconazole-resistant C. parapsilosis in ICUs and intra-abdominal surgery, hypoalbuminemia, and previous fluconazole use. C. parapsilosis isolates and fluconazole resistance should be continuously monitored, strict infection control measures should be taken and antifungal stewardship programs should be implemented.
Sections du résumé
BACKGROUND
BACKGROUND
Candida species are among the most important invasive pathogens in intensive care units (ICUs). Non-albicans species including Candida parapsilosis (C. parapsilosis) has increased in recent years. Fluconazole is the leading antifungal agent but resistance is a concern among C. parapsilosis species.
OBJECTIVES
OBJECTIVE
The aim of this study was to determine the factors associated with fluconazole resistance in patients with candidemia due to C. parapsilosis in ICUs.
METHODS
METHODS
This case-case study was conducted in a 750-bed, tertiary hospital between 2015 and 2021. Patients with fluconazole-resistant C. parapsilosis candidemia constituted the 'cases of interest' group and patients with fluconazole-susceptible C. parapsilosis candidemia constituted the 'comparison cases' group. Demographic and clinical data of the patients were recorded. Logistic regression analysis was performed using the backward elimination method to determine the independent predictors of fluconazole-resistant C. parapsilosis bloodstream infections.
RESULTS
RESULTS
The study included 177 patients. In the cultures of these patients, 76 (43%) fluconazole-resistant, 13 (7.3%) fluconazole-reduced susceptible, and 88 (49.7%) fluconazole-susceptible isolates were found. In the regression analysis the risk factors for fluconazole-resistant C. parapsilosis bloodstream infection, malignancy, immunosuppressive treatment, history of intra-abdominal surgery, hypoalbunemia, previous fluconazole use, and SOFA score were found to be associated in univariate analysis. In multivariate regression analysis, history of intra-abdominal surgery (OR: 2.16; 95% CI: 1.05-4.44), hypoalbuminemia (OR: 2.56; 95% CI: 1.06-6.17) and previous fluconazole use (OR: 3.35; 95% CI: 1.02-11) were found to be independent predictors.
CONCLUSIONS
CONCLUSIONS
In this study, a significant correlation was found between candidemia due to fluconazole-resistant C. parapsilosis in ICUs and intra-abdominal surgery, hypoalbuminemia, and previous fluconazole use. C. parapsilosis isolates and fluconazole resistance should be continuously monitored, strict infection control measures should be taken and antifungal stewardship programs should be implemented.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13717Informations de copyright
© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.
Références
Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta‐analysis. Clin Microbiol Infect. 2019;25(10):1200‐1212.
Tóth R, Nosek J, Mora‐Montes HM, et al. Candida parapsilosis: from genes to the bedside. Clin Microbiol Rev. 2019;32(2):e00111‐18. doi: 10.1128/CMR.00111‐18.
Ning Y, Xiao M, Perlin DS, et al. Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan‐echinocandin resistant case in China. Emerg Microbes Infect. 2023;12(1):2153086.
Hallen‐Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8(3):352‐358.
Branco J, Miranda IM, Rodrigues AG. Candida parapsilosis virulence and antifungal resistance mechanisms: a comprehensive review of key determinants. J Fungi (Basel). 2023;9(1):80. doi:10.3390/jof9010080.
Trevijano‐Contador N, Torres‐Cano A, Carballo‐González C, et al. Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID‐19 pandemic. Open Forum Infect Dis. 2022;9(11):ofac605.
Kuhn DM, Mikherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis. 2004;10(6):1074‐1081.
Ece G, Samlioglu P, Akkoclu G, Atalay S, Kose S. The evaluation of the distribution of yeast like fungi Candida Species at a tertiary care center in western Turkey. Int J Med Sci. 2012;9(7):617‐620.
Hancı SY, Derici YK, Ağuş N, et al. Türkiye'nin Batısında 3. Basamak Bir Sağlık Kuruluşunda Kan Kültürlerinde Üreyen Candida Türlerinin Dağılımının ve Antifungal Direnç Paternlerinin Değerlendirilmesi. Haydarpasa Numune Med J. 2015;55(2):107‐115.
Arastehfar A, Daneshnia F, Hilmioğlu‐Polat S, et al. First report of candidemia clonal outbreak caused by emerging fluconazole‐resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother. 2020;64(10):e01001‐20. doi:10.1128/AAC.01001‐20.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1‐e50.
Yamin D, Akanmu MH, Al Mutair A, Alhumaid S, Rabaan AA, Hajissa K. Global prevalence of antifungal‐resistant Candida parapsilosis: a systematic review and meta‐analysis. Trop Med Infect Dis. 2022;7(8):188.doi:10.3390/tropicalmed7080188.
Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol. 1999;37(3):531‐537.
Goemaere B, Becker P, Van Wijngaerden E, et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018;61(2):127‐133.
Routsi C, Meletiadis J, Charitidou E, et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID‐19 pandemic era. Antibiotics (Basel). 2022;11(6):771. doi:10.3390/antibiotics11060771.
Guinea J, Zaragoza Ó, Escribano P, et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population‐based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2014;58(3):1529‐1537.
McCarthya N, Gieseckea J. Case‐case comparisons to study causation of common infectious diseases. Int J Epidemiol. 1999;28(4):764‐768.
Pogreba‐Brown K, Austhof E, Ellingson K. Methodology minute: an overview of the case–case study design and its applications in infection prevention. Am J Infect Control. 2020;48(3):342‐344.
Social Security Institution Health Practice Notice, Part One General Provisions. in Turkish: Sosyal Güvenlik Kurumu Sağlik Uygulama Tebliği, Birinci Bölüm Genel Hükümler. https://www.mevzuat.gov.tr/File/GeneratePdf?mevzuatNo=17229&mevzuatTur=Teblig&mevzuatTertip=5
Govender NP, Patel J, Magobo RE, et al. Emergence of azole‐resistant Candida parapsilosis causing bloodstream infection: results from laboratory‐based sentinel surveillance in South Africa. J Antimicrob Chemother. 2016;71(7):1994‐2004.
Ramos‐Martínez A, Pintos‐Pascual I, Guinea J, et al. Impact of the COVID‐19 pandemic on the clinical profile of candidemia and the incidence of fungemia due to fluconazole‐resistant Candida parapsilosis. J Fungi (Basel). 2022;8(5):451.
Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother. 2004;48(5):1773‐1777.
Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2014;5(7):a019752.
Choi YJ, Kim YJ, Yong D, et al. Fluconazole‐resistant Candida parapsilosis bloodstream isolates with Y132F mutation in ERG11 gene, South Korea. Emerg Infect Dis. 2018;24(9):1768‐1770.
Bonassoli LA, Bertoli M, Svidzinski TI. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect. 2005;59(2):159‐162.
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792‐798.
Nosek J, Holesova Z, Kosa P, Gacser A, Tomaska L. Biology and genetics of the pathogenic yeast Candida parapsilosis. Curr Genet. 2009;55(5):497‐509.
Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167‐193.
Thomaz DY, de Almeida JN Jr, Lima GME, et al. An azole‐resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol. 2018;9:2997.